Latest Pancreas Stories

X-Gen Pharmaceuticals Inc. announces that it has entered into an exclusive distribution agreement with Eurand Pharmaceuticals Inc. for the company's non-branded pancreatic enzyme product (PEP) Pancrelipase. In accordance with the agreement, X-Gen will represent Eurand as its authorized exclusive distribution agent for its currently marketed unbranded product. Consistent with the April 28, 2004 Federal Register Notification (as supplemented in October 2007), Eurand has both an IND and an NDA...

Scientists have discovered a new technique for turning embryonic stem cells into insulin-producing pancreatic tissue in what could prove a significant breakthrough in the quest to find new treatments for diabetes.The University of Manchester team, working with colleagues at the University of Sheffield, were able to genetically manipulate the stem cells so that they produced an important protein known as a "˜transcription factor'.Stem cells have the ability to become any type of cell, so...

YONKERS, N.Y., Nov. 15 /PRNewswire/ -- CureMark(TM), a privately held specialty biotechnology company focused on the treatment of neurological and other diseases by addressing certain key gastrointestinal/pancreatic secretory deficiencies, announces today the signing of a licensing and development agreement to utilize Balchem Corporation's novel drug delivery technologies to optimize CureMark's proprietary enzyme formulation. Under the agreement, Balchem has granted CureMark an exclusive...